Literature DB >> 3527417

Cancer in renal transplant recipients.

G Sakellariou, D Memmos, E Alexopoulos, T Tsobanelis, Z Sinakos, M Papadimitriou.   

Abstract

The incidence of cutaneous malignancies and non-Hodgkin lymphomas is higher in transplant recipients than in the general population. From 1968 to 1984, 200 kidney grafts were transplanted to 180 patients with end-stage renal disease. All patients were on azathioprine (Aza) and prednisolone. In selected cases ALG and/or small doses of CsA were added. Six patients developed malignant tumors (two Kaposi sarcoma, one squamous cell and one squamous plus basal cell skin cancers, one reticulosarcoma, and one glioma). Mean age of patients was 43 years (range 35-53 years), and mean time of appearance of the tumor after transplantation was 62 months (range 24-98 months). Treatment consisted of reduction of the dosage of Aza, surgical removal or local irradiation of the tumor, and chemotherapy in case of systemic involvement (two cases). Three patients died (one Kaposi sarcoma, one reticulosarcoma, and one glioma) 3 to 6 months after diagnosis, and all three had previously been on high doses of Aza. The remaining three cases (one Kaposi) were cured by stopping or decreasing Aza, by excision, and/or local irradiation of the tumor. It seems that late diagnosis and Aza in high dosage are the main factors leading to the rapid dissemination of the initially localized tumor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3527417

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  2 in total

1.  Brainstem glioblastoma in a patient with secondary progressive multiple sclerosis.

Authors:  Vittorio Mantero; Roberto Balgera; Graziella Bianchi; Giorgio Rossi; Andrea Rigamonti; Anna Fiumani; Andrea Salmaggi
Journal:  Neurol Sci       Date:  2015-05-20       Impact factor: 3.307

2.  Glioblastoma in kidney transplant recipients. Report of five cases.

Authors:  Maurizio Salvati; Alessandro Frati; Emanuela Caroli; Natale Russo; Filippo M Polli; Maurizio Domenicucci; Roberto Delfini
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.